Nathalie Bohdan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nathalie Bohdan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Amal Amaghnouje
Laboratory of Biotechnology, Environment, Agrifood, and Health, University of Sidi Mohamed Ben Abdellah (USMBA), Fez B.P. 1796, Morocco
1 shared publication - Andrii A. Kyrylchuk
Institute of Organic Chemistry NAS of Ukraine
1 shared publication - Andriy Grafov
Department of Chemistry, Faculty of Sciences, Helsinki University, 00100 Helsinki, Finland
1 shared publication - Anton Bershak
Oles Honchar Dnipro National University, Dnipro, Ukraine, Ukraine
1 shared publication - Bohza Serhii
Institute of Organic Chemistry, National Academy of Sciences, 02660 Kyiv, Ukraine
1 shared publication - Dalila Bousta
Laboratory of Biotechnology Environment Agrofood and health (LBEAS), Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez 30000, Morocco
1 shared publication
Latest Publications
- Open Access
- 18 November 2026
- Published by MDPI AG in Preprints.org
Benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-diones: Central GABAergic and Serotonergic Effects in Rats and Docking at the GABAA Receptor Benzodiazepine Site
The benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-dione system fuses the 1,4-benzodiazepine framework to a nitrogen-rich triazinone ring, and no member has been evaluated pharmacologically. We asked whether the series is centrally active in rats and whether the scaffold is accommodated at the receptor’s benzodiazepine site. Forty-seven derivatives were docked blind against eight human GABAA receptor cryo-electron microscopy structures and profiled with SwissADME and ProTox-3.0. Six members of series 1 were prepared, four as regioisomer mixtures quantified by two methods. Male Wistar rats (n = 10 per group) received a nominal 10 mg/kg intragastrically, delivering 7.1–9.9 mg/kg of the major regioisomer, in the thiopental-induced sleep test and a predator-odour model of post-traumatic stress disorder. Five compounds prolonged thiopental-induced sleep by 30.6–72.2%, and 1.5 and 1.7 shortened sleep-onset latency by 32.4% and 31.1%. Stress reduced cortical GABA 3.65-fold; 1.5 restored it to a level indistinguishable from intact animals. All compounds except 1.1 raised the cortical serotonin transporter Slc6a4, which diazepam did not. Docking identified a C-3 aryl substituent as the dominant affinity determinant, and 1.1, the only C-3 methyl compound tested, was least active in all three readouts. Members of this series are therefore centrally active in rats, with GABAergic and serotonergic components; benzodiazepine-site mediation remains a docking-based hypothesis.
- 18 November 2026
- Published by MDPI AG in Preprints.org
Open AccessBenzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-diones: Central GABAergic and Serotonergic Effects in Rats and Docking at the GABAA Receptor Benzodiazepine Site
The benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-dione system fuses the 1,4-benzodiazepine framework to a nitrogen-rich triazinone ring, and no member has been evaluated pharmacologically. We asked whether the series is centrally active in rats and whether the scaffold is accommodated at the receptor’s benzodiazepine site. Forty-seven derivatives were docked blind against eight human GABAA receptor cryo-electron microscopy structures and profiled with SwissADME and ProTox-3.0. Six members of series 1 were prepared, four as regioisomer mixtures quantified by two methods. Male Wistar rats (n = 10 per group) received a nominal 10 mg/kg intragastrically, delivering 7.1–9.9 mg/kg of the major regioisomer, in the thiopental-induced sleep test and a predator-odour model of post-traumatic stress disorder. Five compounds prolonged thiopental-induced sleep by 30.6–72.2%, and 1.5 and 1.7 shortened sleep-onset latency by 32.4% and 31.1%. Stress reduced cortical GABA 3.65-fold; 1.5 restored it to a level indistinguishable from intact animals. All compounds except 1.1 raised the cortical serotonin transporter Slc6a4, which diazepam did not. Docking identified a C-3 aryl substituent as the dominant affinity determinant, and 1.1, the only C-3 methyl compound tested, was least active in all three readouts. Members of this series are therefore centrally active in rats, with GABAergic and serotonergic components; benzodiazepine-site mediation remains a docking-based hypothesis.
- Open Access
- 19 August 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 814
New 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice
We report the design and synthesis of a new diazepine derivative, 4-(4-methoxyphenyl)-2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one (VBZ102), and the evaluation of its anxiolytic-like profile, memory impairment effect, and toxicity in Swiss mice. VBZ102 was evaluated for central nervous system effects in an open field, light–dark box, and novel object recognition tests under oral administration for acute and sub-acute treatment. We tested the VBZ102 toxicity in mice through a determination of LD50 values and examination of the biochemical and histopathological parameters. The VBZ102 induced an anxiolytic effect at different doses both in the light–dark box and open field tests. Unlike other benzodiazepines (e.g., bromazepam), a sedative effect was noted only after administration of the VBZ102 at 10.0 mg/kg.
- 19 August 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 814
Open AccessNew 2,3-Benzodiazepine Derivative: Synthesis, Activity on Central Nervous System, and Toxicity Study in Mice
We report the design and synthesis of a new diazepine derivative, 4-(4-methoxyphenyl)-2,3,4,5-tetrahydro-2,3-benzodiazepin-1-one (VBZ102), and the evaluation of its anxiolytic-like profile, memory impairment effect, and toxicity in Swiss mice. VBZ102 was evaluated for central nervous system effects in an open field, light–dark box, and novel object recognition tests under oral administration for acute and sub-acute treatment. We tested the VBZ102 toxicity in mice through a determination of LD50 values and examination of the biochemical and histopathological parameters. The VBZ102 induced an anxiolytic effect at different doses both in the light–dark box and open field tests. Unlike other benzodiazepines (e.g., bromazepam), a sedative effect was noted only after administration of the VBZ102 at 10.0 mg/kg.